RE:"Look what Square found"- FDA newsagreed....nice find.
It would appear that this policy was purpose written to expedite the pathway to market for toraymyxin.
However, much like the very positive interim results of last week, we can't allow positive news or developments to get in the way of raising cheap money and further diluting the stock. why make an effort the elevate the share price and raise money at $1.50 when you can issue stock below 35 cents?
Keep this FDA release under your hat!